Related Experiment Video
Updated: Aug 15, 2026

A Computer-Based Platform for Aiding Clinicians in Eating Disorder Analysis and Diagnosis
Published on: May 10, 2022
Early response to desipramine among women with bulimia nervosa
B Timothy Walsh1, Robyn Sysko, Michael K Parides
1Department of Psychiatry, College of Physicians and Surgeons of Columbia University, New York, New York 10032, USA. btw1@columbia.edu
Objective:
Numerous trials have demonstrated the efficacy of antidepressant medications for the treatment of bulimia nervosa (BN). The current study examined whether early response to medication predicted response to medication at the end of a controlled trial.
Method:
Data from two previously published studies of desipramine (DMI) were used. Seventy-seven patients with BN were included in the analysis. Receiver operating characteristic (ROC) curves were constructed to examine the relation between the percentage reduction in symptoms at each week and failure to respond to antidepressant medication at the end of the trial.
Results:
Eventual nonresponders to DMI could be reliably identified in the first 2 weeks of treatment.
Conclusion:
The current study provides preliminary evidence that patients with BN who will not respond to antidepressant medication can be identified in the first 2 weeks of treatment.
Related Concept Videos
Antidepressant Drugs: MAOIs and Other Agents
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Binge Eating Disorders
Drugs for Treatment of Constipation-Predominant IBS
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists